Parsatuzumab
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition[1].
Product Specifications
CAS Number
[1312797-14-0]
Product Name Alternative
Anti-EGFL7; RG 7414
UNSPSC
12352203
Target
VEGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/parsatuzumab.html
Purity
97.94
Solubility
10 mM in DMSO
Smiles
[Parsatuzumab]
Molecular Weight
(148.22 kDa)
References & Citations
[1]García-Carbonero R, et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist. 2017 Apr;22 (4) :375-e30. |[2]Chinmayee Goda, et al. Dorrance, Epidermal Growth Factor-like 7 As a Novel Therapeutic Target in Mantle Cell Lymphoma. Blood. 138 (S1), 2021:3300.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
